The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial
Open accessAbstract
Background Choroideremia is an X-linked recessive disease that leads to blindness due to mutations in the CHM gene, which encodes the Rab escort protein 1 (REP1). We assessed the effects of retinal gene therapy with an adeno-associated viral (AAV) vector encoding REP1 (AAV.REP1) in patients with this disease.Methods In a multicentre clinical trial, six male patients (aged 35-63 years) with choroideremia were administered AAV.REP1 (0·6-1·0×10(10) genome particles, subfoveal injection). Visual function tests included best corrected visual acuity, microperimetry, and retinal sensitivity tests for comparison of baseline values with 6 months after surgery. This study is registered with ClinicalTrials.gov, number NCT01461213.Findings Despite undergoing retinal detachment, which normally reduces vision, two patients with advanced choroideremia who had low baseline best corrected visual acuity gained 21 letters and 11 letters (more than two and four lines of vision). Four other patients with near normal best corrected visual acuity at baseline recovered to within one to three letters. Mean gain in visual acuity overall was 3·8 letters (SE 4·1). Maximal sensitivity measured with dark-adapted microperimetry increased in the treated eyes from 23·0 dB (SE 1·1) at baseline to 25·3 dB (1·3) after treatment (increase 2·3 dB [95% CI 0·8-3·8]). In all patients, over the 6 months, the increase in retinal sensitivity in the treated eyes (mean 1·7 [SE 1·0]) was correlated with the vector dose administered per mm(2) of surviving retina (r=0·82, p=0·04). By contrast, small non-significant reductions (p>0·05) were noted in the control eyes in both maximal sensitivity (-0·8 dB [1·5]) and mean sensitivity (-1·6 dB [0·9]). One patient in whom the vector was not administered to the fovea re-established variable eccentric fixation that included the ectopic island of surviving retinal pigment epithelium that had been exposed to vector.Interpretation The initial results of this retinal gene therapy trial are consistent with improved rod and cone function that overcome any negative effects of retinal detachment. These findings lend support to further assessment of gene therapy in the treatment of choroideremia and other diseases, such as age-related macular degeneration, for which intervention should ideally be applied before the onset of retinal thinning.Funding UK Department of Health and Wellcome Trust.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite a 28-day oral corticosteroid therapy started 2 days before the first IVT, a regimen similar to that provided in several other clinical studies using IVT or sub-retinal AAV-based gene therapies,41–45 70.7% of lenadogene nolparvovec-treated eyes developed some degree of intraocular inflammation versus 10.2% of placebo-treated eyes.”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As a consequence, wild-type AAV-based gene therapies for ophthalmologic indications generally require relatively high doses and/or administration via subretinal injection, an invasive surgical procedure that requires detachment of photoreceptors from the RPE and reportedly results in transduction of <5% of the retinal surface. 25 – 27”
From Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies (2024) · cites this paper as [26]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Although adeno-associated viral (AAV) vector-mediated retinal gene therapies have demonstrated efficacy”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, a recent phase I trial for choroideremia showed promising signs of efficacy.15”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“Adeno-associated virus has been successful in clinical gene therapy trials for Leber's congenital amaurosis, hemophilia, familial lipoprotein lipase deficiency, and choroideremia.8–15,26,27,60,61”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“A different approach to subretinal injection is a 'two-step ' injection with initiation of a small 'pre-bleb ' using balanced saline solution (BSS) followed by slow propagation of the bleb using the viral vector (MacLaren et al., 2014). A considerable advantage of two-step injection is that it allows bleb propagation at a lower injection pressure (Scruggs et al., 2022).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as MacLaren et al., 2014
In the citing paper
“Significant inflammation was also observed at 1 × 1011 vg in clinical trials for choroideremia.90,102”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [102]
In the citing paper
“Injection protocols dating to 2014 (30, 31) called for a 2-step procedure, which largely avoids causing a break in Bruch's membrane but does not completely eliminate the risk (20, 32).”
From Subretinal therapy: technological solutions to surgical and immunological challenges (2022) · cites this paper as [30]
In the citing paper
“while subretinal viral gene therapy has a favourable safety profile [300]”
From Bruch’s Membrane: A Key Consideration with Complement-Based Therapies for Age-Related Macular Degeneration (2023) · cites this paper as [300]
In the citing paper
“A phase I/II clinical trial of subretinal gene therapy using an AAV2 vector to deliver human REP1 to the outer retina has shown sustained preservation or improvement of visual acuity over 2 to 5 years in patients with advanced disease [MacLaren 2014, Xue 2018].”
From Correcting visual loss by genetics and prosthetics (2020) · cites this paper as MacLaren 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865
LeWitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., Flaherty, A. W., Eskandar, E. N., Kostyk, S. K., Thomas, K., Sarkar, A., Siddiqui, M. S., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70039-4 · Cited by 681
Self-citationJacobson, S. G. (2012) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.298 · Cited by 639
Sieving, P. A., Caruso, R. C., Tao, W., Coleman, H. R., Thompson, D. J. S., Fullmer, K. R., & Bush, R. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600236103 · Cited by 591
Cideciyan, A. V., Jacobson, S. G., Beltran, W. A., Sumaroka, A., Świder, M., Iwabe, S., Román, A. J., Olivares, M. B., Schwartz, S., Komáromy, A. M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218933110 · Cited by 441
AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness
Bennett, J., Ashtari, M., Wellman, J., Marshall, K. A., Cyckowski, L. L., Chung, D. C., McCague, S., Pierce, E. A., Chen, Y., Bennicelli, J. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002865 · Cited by 395
Retinal degeneration in choroideremia: deficiency of rab geranylgeranyl transferase
Seabra, M. C., Brown, M. S., & Goldstein, J. L. (1993) · Science · doi:10.1126/science.8380507 · Cited by 337
Self-citationCloning of a gene that is rearranged in patients with choroideraemia
Cremers, F. P. M., van de Pol, D. J. R., van Kerkhoff, L. P. M., Wieringa, B., & Ropers, H.-H. (1990) · Nature · doi:10.1038/347674a0 · Cited by 333
Self-citationLoeb, J. E., Cordier, W. S., Harris, M. E., Weitzman, M. D., & Hope, T. J. (1999) · Human Gene Therapy · doi:10.1089/10430349950016942 · Cited by 279
Cited by
Sorted by citations
Items 201–300 of 795
Duong, T. T., Vasireddy, V., Ramachandran, P., Herrera, P. S., Leo, L., Merkel, C., Bennett, J., & Mills, J. A. (2018) · Stem Cell Research · doi:10.1016/j.scr.2018.01.009 · Cited by 48
Update on viral gene therapy clinical trials for retinal diseases
Cheng, S.-Y., & Punzo, C. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.159 · Cited by 49
Personalized therapeutic strategies for patients with retinitis pigmentosa
Zheng, A., Li, Y., & Tsang, S. H. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1006192 · Cited by 50
Wang, J.-H., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.10.017 · Cited by 51
Promising and delivering gene therapies for vision loss
Carvalho, L. S., & Vandenberghe, L. H. (2014) · Vision Research · doi:10.1016/j.visres.2014.07.013 · Cited by 51
Microperimetry as an Outcome Measure in Choroideremia Trials: Reproducibility and Beyond
Dimopoulos, I. S., Tseng, C., & MacDonald, I. M. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-19338 · Cited by 49
Evaluation of AAV-DJ vector for retinal gene therapy
Katada, Y., Kobayashi, K., Tsubota, K., & Kurihara, T. (2019) · PeerJ · doi:10.7717/peerj.6317 · Cited by 46
Visual Function at the Atrophic Border in Choroideremia Assessed with Adaptive Optics Microperimetry
Tuten, W. S., Vergilio, G. K., Young, G. J., Bennett, J., Maguire, A. M., Alemán, T. S., Brainard, D. H., & Morgan, J. I. W. (2019) · Ophthalmology Retina · doi:10.1016/j.oret.2019.05.002 · Cited by 48
Hu, S., Du, J., Chen, N., Jia, R., Zhang, J., Liu, X., & Yang, L. (2020) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.61.4.31 · Cited by 48
Test–Retest Repeatability of Microperimetry at the Border of Deep Scotomas
Wu, Z., Jung, J., Ayton, L. N., Luu, C. D., & Guymer, R. H. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-15977 · Cited by 47
Genome engineering in ophthalmology: Application of CRISPR/Cas to the treatment of eye disease
Hung, S. S. C., McCaughey, T., Swann, O. G., Pébay, A., & Hewitt, A. W. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.05.001 · Cited by 49
Ocular delivery of CRISPR/Cas genome editing components for treatment of eye diseases
Yu, W., & Wu, Z. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.011 · Cited by 48
Gene Therapy of Inherited Retinal Degenerations: Prospects and Challenges
Trapani, I., Banfi, S., Simonelli, F., Surace, E. M., & Auricchio, A. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.030 · Cited by 46
The cGMP Pathway and Inherited Photoreceptor Degeneration: Targets, Compounds, and Biomarkers
Tolone, A., Belhadj, S., Rentsch, A., Schwede, F., & Paquet‐Durand, F. (2019) · Genes · doi:10.3390/genes10060453 · Cited by 46
Dysli, C., Wolf, S., Tran, H. V., & Zinkernagel, M. S. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-20392 · Cited by 45
Delivering gene therapy for mucopolysaccharide diseases
Wood, S., & Bigger, B. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.965089 · Cited by 47
Multimodal assessment of choroideremia patients defines pre-treatment characteristics
Seitz, I. P., Zhour, A., Kohl, S., Llavona, P., Peter, T., Wilhelm, B., Zrenner, E., Ueffing, M., Bartz‐Schmidt, K. U., & Fischer, M. D. (2015) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-015-2976-4 · Cited by 45
Pennesi, M. E., Birch, D. G., Duncan, J. L., Bennett, J., & Girach, A. (2019) · Retina · doi:10.1097/iae.0000000000002553 · Cited by 45
Hammadi, S., Tzoumas, N., Ferrara, M., Meschede, I. P., Lo, K., Harris, C., Lako, M., & Steel, D. H. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082870 · Cited by 44
Correlation of structure and function of the macula in patients with retinitis pigmentosa
Battu, R., Khanna, A., Hegde, B., Berendschot, T. T. J. M., Grover, S., & Schouten, J. (2015) · Eye · doi:10.1038/eye.2015.61 · Cited by 44
Mechanism and evidence of nonsense suppression therapy for genetic eye disorders
Richardson, R., Smart, M. J. K., Tracey‐White, D., Webster, A. R., & Moosajee, M. (2017) · Experimental Eye Research · doi:10.1016/j.exer.2017.01.001 · Cited by 48
Self-citationProduction and Application of Multicistronic Constructs for Various Human Disease Therapies
Shaimardanova, A. A., Chulpanova, D. S., Kitaeva, K. V., Abdrakhmanova, I. I., Chernov, V. M., Rutland, C. S., Rizvanov, A. A., & Solovyeva, V. V. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11110580 · Cited by 45
Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina
Chandler, L. C., McClements, M. E., Yusuf, I. H., Martinez-Fernandez de la Camara, C., MacLaren, R. E., & Xue, K. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.05.011 · Cited by 43
Self-citationYang, P. G., Pardon, L. P., Ho, A. C., Lauer, A. K., Yoon, D., Boye, S. L., Boye, S. L., Román, A. J., Wu, V. F., Garafalo, A. V., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01447-8 · Cited by 43
Ophthalmic manifestations of inherited neurodegenerative disorders
Kersten, H. M., Roxburgh, R. H., & Danesh-Meyer, H. V. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.79 · Cited by 43
Genetic manipulation for inherited neurodegenerative diseases: myth or reality?
Yu‐Wai‐Man, P. (2016) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2015-308329 · Cited by 43
Soens, Z. T., Branch, J., Wu, S., Yuan, Z., Li, Y., Li, H., Wang, K., Xu, M., Rajan, L., Motta, F. L., et al. (2017) · Human Mutation · doi:10.1002/humu.23294 · Cited by 42
Implantation of electronic visual prosthesis for blindness restoration
Jang, J., Kim, H., Song, Y. M., & Park, J. (2019) · Optical Materials Express · doi:10.1364/ome.9.003878 · Cited by 43
Boye, S. L., Peterson, J. J., Choudhury, S., Min, S. H., Ruan, Q., McCullough, K. T., 张忠红, Olshevskaya, E. V., Peshenko, I. V., Hauswirth, W. W., et al. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.053 · Cited by 41
Focused Update on AAV-Based Gene Therapy Clinical Trials for Inherited Retinal Degeneration
Fuller-Carter, P. I., Basiri, H., Harvey, A. R., & Carvalho, L. S. (2020) · BioDrugs · doi:10.1007/s40259-020-00453-8 · Cited by 41
Recent advances and future prospects in choroideremia
Zinkernagel, M., & MacLaren, R. E. (2015) · Clinical ophthalmology · doi:10.2147/opth.s65732 · Cited by 41
Self-citationGaranto, A., van der Velde-Visser, S. D., Cremers, F. P. M., & Collin, R. W. J. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-75402-4_11 · Cited by 41
Self-citationThe influence of subretinal injection pressure on the microstructure of the monkey retina
Takahashi, K., Morizane, Y., Hisatomi, T., Tachibana, T., Kimura, S., Hosokawa, M. M., Shiode, Y., Hirano, M., Doi, S., Toshima, S., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0209996 · Cited by 41
TALEN-Mediated Gene Targeting for Cystic Fibrosis-Gene Therapy
Xia, E., Zhang, Y., Cao, H., Li, J., Duan, R. C., & Hu, J. (2019) · Genes · doi:10.3390/genes10010039 · Cited by 41
Genetics, pathogenesis and therapeutic developments for Usher syndrome type 2
Stemerdink, M., García‐Bohórquez, B., Schellens, R. T. W., García‐García, G., van Wijk, E., & Millán, J. M. (2021) · Human Genetics · doi:10.1007/s00439-021-02324-w · Cited by 42
Adeno-Associated Virus Serotype 2–hCHM Subretinal Delivery to the Macula in Choroideremia
Alemán, T. S., Huckfeldt, R. M., Serrano, L. W., Pearson, D. J., Vergilio, G. K., McCague, S., Marshall, K. A., Ashtari, M., Doan, T. M., Weigel-DiFranco, C., et al. (2022) · Ophthalmology · doi:10.1016/j.ophtha.2022.06.006 · Cited by 42
Spectrum of Disease Severity and Phenotype in Choroideremia Carriers
Jauregui, R., Park, K. S., Tanaka, A. J., Cho, A., Paavo, M., Zernant, J., Francis, J. H., Allikmets, R. L., Sparrow, J. R., & Tsang, S. H. (2019) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2019.06.002 · Cited by 40
Vasconcelos, H. M., Lujan, B. J., Pennesi, M. E., Yang, P., & Lauer, A. K. (2020) · International Journal of Retina and Vitreous · doi:10.1186/s40942-020-00216-1 · Cited by 39
Simunovic, M. P., Moore, A. T., & MacLaren, R. E. (2016) · Translational Vision Science & Technology · doi:10.1167/tvst.5.3.10 · Cited by 39
Self-citationFocused ultrasound as a novel strategy for noninvasive gene delivery to retinal Müller glia
Touahri, Y., Dixit, R., Kofoed, R. H., Miloska, K., Park, E., Raeisossadati, R., Markham-Coultes, K., David, L. A., Rijal, H., Zhao, J., et al. (2020) · Theranostics · doi:10.7150/thno.42611 · Cited by 40
Recent advances and future prospects in choroideremia
Zinkernagel, M. S., & MacLaren, R. E. (2015) · doi:10.7892/boris.75867 · Cited by 39
Self-citationOchakovski, G. A., Peters, T., Michalakis, S., Wilhelm, B., Wissinger, B., Biel, M., Bartz-Schmidt, K. U., Fischer, M. D., & for the RD-CURE Consortium (2017) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-22402 · Cited by 38
Hashida, N., & Nishida, K. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114870 · Cited by 37
Sun, D., Maeno, H., Gujrati, M. D., Schur, R. M., Maeda, A., Maeda, T., Palczewski, K., & Lu, Z. (2015) · Macromolecular Bioscience · doi:10.1002/mabi.201500192 · Cited by 38
Wu, Y., Jiang, L., Geng, H., Yang, T., Han, Z., He, X.-B., Lin, K., & Xu, F. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.05.005 · Cited by 40
Optimisation of dark adaptation time required for mesopic microperimetry
Han, R. C., Gray, J. M., Han, J., MacLaren, R. E., & Jolly, J. K. (2018) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2018-312253 · Cited by 38
Self-citationOutcome Measures Used in Ocular Gene Therapy Trials: A Scoping Review of Current Practice
Jolly, J. K., Bridge, H., & MacLaren, R. E. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01076 · Cited by 38
Self-citationSalman, A., Kantor, A., McClements, M. E., Marfany, G., Trigueros, S., & MacLaren, R. E. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091842 · Cited by 37
Self-citationApplications of antisense oligonucleotides for the treatment of inherited retinal diseases
Collin, R. W. J., & Garanto, A. (2017) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000363 · Cited by 38
A Robust System for Production of Superabundant VP1 Recombinant AAV Vectors
Qizhao, W., Wu, Z., Zhang, J., Firrman, J., Wei, H., Zhuang, Z., Liu, L., Miao, L., Hu, Y., Li, D., et al. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.002 · Cited by 37
Retinal Degeneration in Choroideremia follows an Exponential Decay Function
Aylward, J. W., Xue, K., Patrício, M. I., Jolly, J. K., Wood, J. C., Brett, J., Jasani, K., & MacLaren, R. E. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.02.004 · Cited by 37
Self-citationZuvin, M., Kuruoglu, E., Kaya, V. O., Unal, O., Kutlu, Ö., Acar, H. Y., Gözüaçık, D., & Koşar, A. (2019) · ACS Omega · doi:10.1021/acsomega.9b01000 · Cited by 37
Retinal Dystrophies and the Road to Treatment: Clinical Requirements and Considerations
Talib, M., & Boon, C. J. F. (2020) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000290 · Cited by 37
Pathogenic mechanisms and the prospect of gene therapy for choroideremia
Dimopoulos, I. S., Chan, S., MacLaren, R. E., & MacDonald, I. M. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1046434 · Cited by 37
Self-citationCorrection of Monogenic and Common Retinal Disorders with Gene Therapy
Sengillo, J. D., Justus, S., Cabral, T., & Tsang, S. H. (2017) · Genes · doi:10.3390/genes8020053 · Cited by 39
Sobh, M., Lagali, P. S., Ghiasi, M., Montroy, J. R., Dollin, M. L., Hurley, B. R., Leonard, B. C., Dimopoulos, I. S., Lafreniere, M., Fergusson, D. A., et al. (2023) · Translational Vision Science & Technology · doi:10.1167/tvst.12.11.24 · Cited by 35
Maria, M., Ajmal, M., Azam, M., Waheed, N. K., Siddiqui, S. N., Mustafa, B., Ayub, H., Ali, L., Ahmad, S., Micheal, S., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119806 · Cited by 36
Self-citationConcise Review: The Potential Use of Intestinal Stem Cells to Treat Patients with Intestinal Failure
Hong, S. N., Dunn, J., Stelzner, M. G., & Martı́n, M. G. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2016-0153 · Cited by 36
Fujita, K., Nishiguchi, K. M., Shiga, Y., & Nakazawa, T. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.04.003 · Cited by 37
KCNV2 retinopathy: clinical features, molecular genetics and directions for future therapy
de Guimarães, T. A. C., Georgiou, M., Robson, A. G., & Michaelides, M. (2020) · Ophthalmic Genetics · doi:10.1080/13816810.2020.1766087 · Cited by 36
Prenylation defects in inherited retinal diseases
Roosing, S., Collin, R. W. J., den Hollander, A. I., Cremers, F. P. M., & Siemiatkowska, A. M. (2014) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2013-102138 · Cited by 35
Self-citationThe application and progression of CRISPR/Cas9 technology in ophthalmological diseases
Hu, X., Zhang, B., Li, X., Li, M., Wang, Y., Dan, H., Zhou, J., Wei, Y., Ge, K., Li, P., et al. (2022) · Eye · doi:10.1038/s41433-022-02169-1 · Cited by 37
Sanjurjo-Soriano, C., & Kalatzis, V. (2018) · Neural Plasticity · doi:10.1155/2018/5056279 · Cited by 38
Neurotrophin gene therapy to promote survival of spiral ganglion neurons after deafness
Leake, P. A., Akil, O., & Lang, H. (2020) · Hearing Research · doi:10.1016/j.heares.2020.107955 · Cited by 35
Membrane trafficking in the retinal pigment epithelium at a glance
Storm, T., Burgoyne, T., & Futter, C. E. (2020) · Journal of Cell Science · doi:10.1242/jcs.238279 · Cited by 34
Sizikov, A. A., Kharlamova, M. V., Nikitin, M. P., Nikitin, P. I., & Kolychev, E. L. (2021) · Nanomaterials · doi:10.3390/nano11051078 · Cited by 35
Sahel, J., Grieve, K. F., Pagot, C., Authié, C., Mohand‐Saïd, S., Pâques, M., Audo, I. S., Becker, K., Chaumet-Riffaud, A.-E., Azoulay-Sebban, L., et al. (2021) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2021.04.013 · Cited by 36
Retinal cadherins and the retinal cadherinopathies: Current concepts and future directions
Yusuf, I. H., Garrett, A. M., MacLaren, R. E., & Issa, P. C. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.101038 · Cited by 37
Self-citationDimopoulos, I. S., Radziwon, A., Laurent, C. D. S., & MacDonald, I. M. (2017) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000392 · Cited by 35
Lad, E. M., Duncan, J. L., Liang, W., Maguire, M. G., Ayala, A. R., Audo, I. S., Birch, D. G., Carroll, J., Cheetham, J. K., Durham, T. A., et al. (2022) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2022.08.013 · Cited by 35
A novel retinal ganglion cell promoter for utility in AAV vectors
Hanlon, K. S., Chadderton, N., Palfi, A., Blanco Fernandez, A., Humphries, P., Kenna, P. F., Millington-Ward, S., & Farrar, G. J. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00521 · Cited by 34
Emmerling, V. V., Fischer, S., Stiefel, F., Holzmann, K., Handrick, R., Hesse, F., Hörer, M., Kochanek, S., & Otte, K. (2015) · Biotechnology and Bioengineering · doi:10.1002/bit.25853 · Cited by 34
Manufacturing of recombinant adeno-associated viral vectors: new technologies are welcome
Ayuso, E. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2015.49 · Cited by 35
Tshilenge, K., Ameline, B., Weber, M., Mendes-Madeira, A., Nédellec, S., Biget, M., Provost, N., Libeau, L., Blouin, V., Deschamps, J., et al. (2016) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.034 · Cited by 34
Parodi, M. B., Arrigo, A., MacLaren, R. E., Aragona, E., Toto, L., Mastropasqua, R., Manitto, M. P., & Bandello, F. M. (2018) · Retina · doi:10.1097/iae.0000000000002118 · Cited by 34
Self-citationOptical Coherence Tomography Angiography Imaging in Inherited Retinal Diseases
Ong, S. S. Y., Patel, T. P., & Singh, M. S. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122078 · Cited by 34
Enhanced selective gene delivery to neural stem cells in vivo by an adeno-associated viral variant
Kotterman, M. A., Vazin, T., & Schaffer, D. V. (2015) · Development · doi:10.1242/dev.115253 · Cited by 32
Duong, T. T., Lim, J., Vasireddy, V., Papp, T., Nguyen, H., Leo, L., Pan, J., Zhou, S., Chen, H. I., Bennett, J., et al. (2019) · Stem Cells International · doi:10.1155/2019/7281912 · Cited by 33
Lohia, A., Sahel, D. K., Salman, M., Singh, V., Mariappan, I., Mittal, A., & Chitkara, D. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2022.02.001 · Cited by 33
Teo, K. Y. C., Lee, S. Y., Barathi, A. V., Tun, S. B. B., Tan, L., & Constable, I. J. (2018) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.18-24333 · Cited by 33
Novel technique for subretinal injection using local removal of the internal limiting membrane
Okanouchi, T., Toshima, S., Kimura, S., Morizane, Y., & Shiraga, F. (2016) · Retina · doi:10.1097/iae.0000000000001029 · Cited by 33
Wang, J., Zhang, J., Yu, S., Li, H., Chen, S., Luo, J., Wang, H., Guan, Y., Zhang, H., Yin, S., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01806-3 · Cited by 34
Update on Clinical Trial Endpoints in Gene Therapy Trials for Inherited Retinal Diseases
Igoe, J., Lam, B. L., & Gregori, N. Z. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13185512 · Cited by 33
Ovando-Roche, P., Georgiadis, A., Smith, A. J., Pearson, R. A., & Ali, R. R. (2017) · Current Stem Cell Reports · doi:10.1007/s40778-017-0078-4 · Cited by 35
Choroideremia: molecular mechanisms and development of AAV gene therapy
Patrício, M. I., Barnard, A. R., Xue, K., & MacLaren, R. E. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1484448 · Cited by 34
Self-citationRevolution in Gene Medicine Therapy and Genome Surgery
Jiang, D. J., Xu, C. L., & Tsang, S. H. (2018) · Genes · doi:10.3390/genes9120575 · Cited by 33
Zhou, Y., Yu, M., Tie, C., Deng, Y., Wang, J., Yi, Y., Zhang, F., Huang, C., Zheng, H., Mei, L., et al. (2021) · Research · doi:10.34133/2021/9760398 · Cited by 33
In Vivo Imaging of Subretinal Bleb-Induced Outer Retinal Degeneration in the Rabbit
Bartuma, H., Petrus-Reurer, S., Aronsson, M., Westman, S., André, H., & Kvanta, A. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-16208 · Cited by 33
Gene Delivery of a Viral Anti-Inflammatory Protein to Combat Ocular Inflammation
Ildefonso, C. J., Jaime, H., Rahman, M. M., Li, Q., Boye, S. L., Hauswirth, W. W., Lucas, A., McFadden, G., & Lewin, A. S. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.089 · Cited by 33
Bočkor, L., Bortolussi, G., Iaconcig, A., Chiaruttini, G., Tiribelli, C., Giacca, M., Benvenuti, F., Zentilin, L., & Muro, A. F. (2017) · Gene Therapy · doi:10.1038/gt.2017.75 · Cited by 32
Black, A., Vasireddy, V., Chung, D. C., Maguire, A. M., Gaddameedi, R., Tolmachova, T., Seabra, M. C., & Bennett, J. (2014) · The Journal of Gene Medicine · doi:10.1002/jgm.2768 · Cited by 33
Self-citationCosta, R. D., Röger, C., Segelken, J., Barben, M., Grimm, C., & Neidhardt, J. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-19701 · Cited by 31
Torriano, S., Erkilic, N., Baux, D., Cereso, N., DeLuca, V. J., Meunier, I., Moosajee, M., Roux, A., Hamel, C., & Kalatzis, V. (2018) · Scientific Reports · doi:10.1038/s41598-018-26481-7 · Cited by 31
Patient-reported outcome measures in inherited retinal degeneration gene therapy trials
Lacy, G. D., Abalem, M. F., Musch, D. C., & Jayasundera, T. (2020) · Ophthalmic Genetics · doi:10.1080/13816810.2020.1731836 · Cited by 32
The argus ii retinal prosthesis system
Bloch, E., & da Cruz, L. (2020) · Prosthesis · doi:10.5772/intechopen.84947 · Cited by 31
The physiology of the retinal pigment epithelium in Danon disease
Thompson, D. A., Constable, P. A., Liasis, A., Walters, B., & Esteban, M. T. (2016) · Retina · doi:10.1097/iae.0000000000000736 · Cited by 31
Wood, L. J., Jolly, J. K., Josan, A. S., Buckley, T. M. W., & MacLaren, R. E. (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.2.28 · Cited by 31
Self-citationChoroideremia: molecular mechanisms and therapies
Sarkar, H., & Moosajee, M. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.02.011 · Cited by 35
Toward low-cost gene therapy: mRNA-based therapeutics for treatment of inherited retinal diseases
Antas, P., Carvalho, C., Cabral-Teixeira, J., de Lemos, L., & Seabra, M. C. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.11.009 · Cited by 34
Self-citationKelbsch, C., Maeda, F., Lisowska, J., Lisowski, Ł., Straßer, T., Stingl, K. T., Wilhelm, B., Wilhelm, H. M., & Peters, T. M. (2016) · Acta Ophthalmologica · doi:10.1111/aos.13259 · Cited by 33
Metadata
- Authors
- MacLaren, R. E., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Seymour, L., Clark, K. R., During, M. J., Cremers, F. P. M., Black, G. C. M., Lotery, A. J., Downes, S. M., Webster, A. R., & Seabra, M. C.
- Affiliations
- Moorfields Eye Hospital NHS Foundation Trust (GB)
- University of Oxford (GB)
- NIHR Oxford Biomedical Research Centre (GB)
- Imperial College London (GB)
- Nationwide Children's Hospital (US)
- The Ohio State University Wexner Medical Center (US)
- Radboud University Nijmegen (NL)
- Manchester Academic Health Science Centre (GB)
- University of Southampton (GB)
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2014-03
- Volume
- 383
- Issue
- 9923
- Pages
- 1129-1137
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC4171740
- OpenAlex
- W2126115955
- Cited by
- 796
- References
- 28
- Citations by year
- 2026: 24 · 2025: 29 · 2024: 46 · 2023: 42 · 2022: 37 · 2021: 62 · 2020: 68 · 2019: 78 · 2018: 85 · 2017: 109 · 2016: 80 · 2015: 83 · 2014: 51
- FWCI
- 44.12
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Lancet (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- Wellcome Trust (091984)
- Cancer Research UK (11339)
- National Institute for Health and Care Research (NF-SI-0509-10185)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- choroideremia, retinal gene therapy, adeno-associated virus vectors, Rab escort protein 1, CHM gene, X-linked retinal degeneration, visual acuity improvement, retinal sensitivity, microperimetry, retinal detachment, vector dose, rod and cone function, retinal pigment epithelium, eccentric fixation, blindness treatment
- MeSH terms
- Adenoviridae, Adult, Aged, Fluorescence, Genetic Vectors, Humans, Male, Middle Aged, Retinal Detachment, Visual Acuity, Genetic Therapy, Choroideremia, Gene Transfer Techniques, Transgenes, Adaptor Proteins, Signal Transducing, Injections, Intraocular
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
